GlassScriptPhysician profile
Sandra M Brown
NPI 1356383509
$2,993.06
in general payments reported to CMS, 2019-2025
23 companies · $253 in 2025
The $253 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $152 · 2022: $1,713 · 2023: $277 · 2024: $597 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,057 · Education: $70.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,057.18 |
| Education | $70.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eagle Pharmaceuticals, INC. | $1,486.24 | 2022 | |
| Abbott Laboratories | $351.93 | 2024 | Proclaim, Eterna |
| Seagen INC. | $203.35 | 2021-2023 | Tukysa |
| Pharmacyclics LLC, An Abbvie Company | $143.37 | 2021-2023 | Epkinly, Imbruvica |
| Pfizer INC. | $111.41 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $88.63 | 2025 | Keytruda, Lynparza, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $75.09 | 2024-2025 | Enhertu |
| Novartis Pharmaceuticals Corporation | $59.25 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.31 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $52.24 | 2022-2025 | Opdivo |
| Daiichi Sankyo INC. | $51.50 | 2021-2024 | Enhertu |
| Regeneron Healthcare Solutions, INC. | $49.81 | 2022-2024 | Libtayo |
| Array Biopharma INC | $48.80 | 2025 | Mektovi, Tukysa, Braftovi |
| Incyte Corporation | $36.60 | 2022-2023 | Monjuvi, Pemazyre |
| Pharmaand Gmbh | $33.19 | 2024 | Rubraca |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $30.93 | 2022 | |
| Eisai INC. | $20.67 | 2022 | |
| Puma Biotechnology, INC. | $18.81 | 2023 | Nerlynx |
| Deciphera Pharmaceuticals INC. | $17.58 | 2024 | Qinlock |
| Global Blood Therapeutics, INC. | $17.16 | 2022 | |
| Mirati Therapeutics, INC. | $16.87 | 2023 | Krazati |
| Janssen Biotech, INC. | $16.83 | 2022 | |
| Clovis Oncology, INC. | $6.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.